FDA-cleared profile

Arterys MICA

Arterys Inc.

Support-tool image processing for quantitative cardiovascular assessment and oncologic lesion evaluation, quantification, follow-up, and documentation to aid trained healthcare professionals in diagnosis; the software does not directly generate a diagnosis or potential findings.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Support-tool image processing for quantitative cardiovascular assessment and oncologic lesion evaluation, quantification, follow-up, and documentation to aid trained healthcare professionals in diagnosis; the software does not directly generate a diagnosis or potential findings.
FDA source Exact FDA submission Checked 2026-09-09
Intended users
Trained healthcare professionals.
FDA source Exact FDA submission Checked 2026-09-09
Care setting and population
Diagnostic and therapy follow-up examinations.
FDA source Exact FDA submission Checked 2026-09-09
Workflow role
Image viewing, storage, transfer, filtering, digital manipulation, quantitative measurement, cardiovascular flow and ventricular-function analysis, and oncology lesion follow-up and documentation.
FDA source Exact FDA submission Checked 2026-09-09
Required input
Pre-existing DICOM or non-DICOM medical data, including CT or MR images uploaded from a PACS or scanner; Cardio AI supports 1.5T and 3.0T cardiovascular MR images, and Oncology AI processes MR or CT images.
FDA source Exact FDA submission Checked 2026-09-09
Output and human action
Stored, processed, and transferred images and patient information; filtered and digitally manipulated images; quantitative cardiovascular data for blood flow and ventricular function; and oncology lesion presence, evaluation, quantification, follow-up, and documentation support.
FDA source Exact FDA submission Checked 2026-09-09
Limitations
Arterys MICA provides image and related information for interpretation by a trained professional and does not directly generate a diagnosis or potential findings. Cardio AI validation is stated for 1.5T and 3.0T MR scanners; the client requires monitors meeting appropriate technical specifications for image diagnosis.
FDA source Exact FDA submission Checked 2026-09-09

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K192437
FDA source Exact FDA submission Checked 2026-08-31
Modality
CT/CTA; MRI
FDA source Exact FDA submission Checked 2026-09-09
Anatomy
Heart and major vessels for Cardio AI; oncology lesion anatomy is not further specified in the FDA statement.
FDA source Exact FDA submission Checked 2026-09-09
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2020-03-25
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The system has a Chrome desktop-browser client and Linux server, receives pre-existing images from a PACS or scanner, and manages DICOM and non-DICOM data, images, and patient information. The packet does not establish a specific local PACS, RIS, EHR, or interface version.
FDA source Exact FDA submission Checked 2026-09-09
Deployment and data flow
On-cloud
Public source Exact FDA submission Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-09

Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-09

Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-09

Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for Arterys MICA; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
Safety and performance were evaluated through software verification and validation against IEC 62304, ISO 14971, and FDA software and cybersecurity guidance. The packet reports hundreds of verification and validation tests, including mammography display-quality testing and comparison to Medis MR-CT VVA, but provides no numeric sensitivity, specificity, AUC, Dice, correlation, or reader-delta endpoint.
FDA source Exact FDA submission Checked 2026-09-09
Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-09-09

No public price or quote for the exact K192437 configuration was established in this review.

Reimbursement and coding
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-09

No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K192437. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Public source Exact FDA submission Checked 2026-09-09

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-09Last searched
18Fields reviewed
9Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA scope controls clinical claims. ACR provides bounded exact-submission catalog context. Candidate literature metadata remains a discovery queue until full-text identity, endpoint, population, and version review is completed. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-09.

Alternatives

Related tools to compare

FDA-cleared K182034

Arterys MICA

Arterys Inc.

DICOM/non-DICOM image and data management with optional quantitative cardiac MR and oncology lesion evaluation, quantification, follow-up, and documentation support; the software...

Modality
CT/CTA; MRI
Anatomy
Heart and major vessels for the optional Cardio AI module; lung and liver lesions or nodules for the optional Oncology AI module; the base viewer handles broader radiological image data.
Decision
2018-10-17
FDA-cleared K242781

cvi42 Software Application

Circle Cardiovascular Imaging Inc.

View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive...

Modality
CT/CTA; MRI
Anatomy
Cardiovascular system; heart, coronary and adjacent vessels, and cardiac valves
Decision
2024-10-15
FDA-cleared K173542

Arterys Oncology DL

Arterys Inc.

Oncology imaging workflow for viewing, manipulating, 3D visualizing, and comparing images and assessing/documenting morphological changes at diagnostic and therapy follow-up;...

Modality
CT/CTA; MRI
Anatomy
Oncologic lesions, with semi-automated segmentation explicitly described for lung nodules and liver lesions.
Decision
2018-01-25
FDA-cleared K231683

inHEART Models

inHEART, SAS

Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.

Modality
CT/CTA; MRI
Anatomy
Cardiac structures, including the aorta, atria, ventricles, pulmonary artery trunk, and right atrium/inferior vena cava structures described in the FDA performance table
Decision
2024-02-29